Kivorent News

Wednesday, November 18, 2026

Health techExplainer

How the FDA regulates the apps drugmakers ship with their medicines

The FDA's final guidance on prescription drug use-related software treats what a drugmaker's app shows patients and clinicians as drug labeling. Here is how that works, and when an app earns a place on the prescribing label.

Docket, covering health regulation and AI in care
, 3 min read

2023year the FDA first proposed these rules in draft

What to know

  • Software a drugmaker distributes about its own drug is called prescription drug use-related software, or PDURS.
  • The FDA treats what that software shows users as prescription drug labeling, usually promotional labeling.
  • Apps tied to a device used with the drug generally belong in the prescribing information; standalone apps need to show they are essential or clinically beneficial.

Many prescription drugs now come with an app. An inhaler may pair with software that logs each puff. A shot may come with a dose reminder, a symptom tracker or a coaching program. On October 20, 2026, the FDA's drug center (CDER) finalized guidance on how it views that software, nearly three years after a September 2023 draft, according to RAPS and Pharmaceutical Commerce. The document goes by the name prescription drug use-related software, or PDURS.

What counts as PDURS

The guidance covers software that a drug's sponsor, or someone acting for it, distributes and that produces an "end-user output" connected to the sponsor's own drugs. End-user output is whatever the software presents to a patient, a caregiver or a health care professional: a screen, a chart, a reminder, a message.

Two details widen the scope. It does not matter whether the sponsor built the app or hired a technology partner to build it. And it applies whether or not the software is also regulated as a medical device, Pharmaceutical Commerce reports. Adherence and coaching tools offered through a manufacturer's patient support program are included when the sponsor or its vendor provides them.

Software a hospital or an independent developer makes on its own, without the drugmaker, is outside this framework. That software may still fall under the FDA's device rules, which are explained in our guide to clearance, approval and De Novo.

Why the output is treated as labeling

In drug law, labeling means more than the sticker on the bottle. It includes written, printed or graphic material that accompanies a product. The FDA's view is that an app's output is a form of prescription drug labeling, which brings it under the same rules that govern a drugmaker's other materials.

There are two kinds of labeling in play. FDA-required labeling is the prescribing information the agency reviews and approves as part of the drug's application. Promotional labeling is the sponsor's own material about the drug, which must be truthful, balanced and consistent with the approved label. According to RAPS, the agency says that in most cases, what a companion app shows users will be treated as promotional material, as with other drug advertising.

When an app makes it onto the prescribing label

The guidance splits software into two groups.

Device-connected software works with a device used with the drug, such as an app linked to a sensor-equipped inhaler or injector. The FDA says this software should generally be described in the drug's prescribing information. The final version adds a recommended statement for the label when such software has not been shown to meaningfully improve a clinical outcome, so readers can tell what the app does and does not do.

Standalone software works without a device, like a dose reminder or symptom diary. It belongs in the prescribing information only if the sponsor shows the app is essential to using the drug safely and effectively, or that it delivers a meaningful clinical benefit. Otherwise its content is promotional. Showing a clinical benefit typically takes evidence from clinical studies, such as those described in our explainer on randomized controlled trials.

What changed from the draft

Both trade reports list the same changes from 2023. The final guidance adds a decision tree to help sponsors work out which kind of labeling applies, examples of how device-connected and standalone software can be described in prescribing information, and the label statement for software without proven clinical benefit. It also replaces the phrase digital health technologies with software with prescription drugs. Sponsors do not need to resubmit an app's output after a software update that leaves previously submitted content unchanged. The FDA says it is aligning its approach across its drug and device centers so software that is also a device can get coordinated review.

Like all FDA guidance, the document states the agency's current thinking. It is not a binding regulation.

Why it matters

Drug companion apps are becoming a routine part of how medicines are sold and used. This guidance tells drugmakers that what their apps say is held to drug-labeling standards, and that a claim of real clinical benefit on the official label has to be earned with evidence. For patients and clinicians, it means an app mentioned in the prescribing information has had more scrutiny than one that is simply offered alongside a drug. It also fits a wider FDA push to sort out how software in care is overseen, from updates to AI devices to wellness products.

This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.

Sources

FDA and health regulationDigital health and AI in care

Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.